GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) Indication For Use In Patients With Severe Aplastic Anaemia

By: via Benzinga
GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.